On-Demand Webinar: Efficacy of Polyfunctional GD3 CAR T Cells against Rare Tumors

Tuberous sclerosis complex (TSC) is a rare genetic disorder that triggers the development of benign tumors in various parts of the body, often affecting multiple vital organs. With no cure available for this disorder and traditional treatments often requiring invasive surgical techniques, investigators have begun to look toward the success of immunotherapies in treating and managing other diseases.

In this on-demand webinar, Dr. I. Caroline Le Poole, Professor of Dermatology and Microbiology-Immunology, Northwestern University Feinberg School of Medicine, will discuss identifying benign TSC tumors expressing immunogens that can be targeted by CAR T therapy. Moreover, she will highlight recently published data showing that polyfunctional GD3 CAR T cells created to target the TSC tumor immunogens could substantially reduce tumor burden in a mouse model. We will also learn how single-cell multiplex cytokine profiling via IsoPlexis’ proteomics platform was utilized to uncover rare polyfunctional CAR T cell subsets indicating the functional capacity for improved anti-tumor response.

Click below to view the on-demand webinar:

Share This Article
Subscribe to Follow the Data

Weekly email to keep you at the forefront of single-cell & multiplexed proteomics.